Jared Baeten

Stories

FDA approves Gilead's Bixlenvo, a single-tablet option for HIV patients on complex regimens

Leads the lenacapavir portfolio that anchors Bixlenvo

Roughly 5% of Americans living with HIV take their antiretrovirals as several pills a day, because resistance, side effects, or other medications rule out standard single tablets. On Thursday the FDA approved a pill built for that group.

Updated Yesterday